Extracts of human term amniotic, placental, and chorion/ decidua tissue contained, respectively, 4·36 2·79 (pmol/g wet wt; mean ...; n=5), 2·78 0·5 (n=5) and 0·68 0·68 (n=5) peptide YY (PYY)-like immunoreactivity. Using a specific PYY antiserum, gel filtration chromatography and reverse-phase high performance liquid chromatography (HLPC), amniotic, placental and fetal intestinal tissue extracts were demonstrated to contain PYY-like immunoreactivity consisting of equal amounts of PYY 1-36 and PYY . The presence of pancreatic polypeptide was not detected in any of the extracts.
Introduction
The pancreatic polypeptide (PP) family of peptides -PP, peptide YY (PYY) and neuropeptide Y (NPY) -is unique in that all recognized members were originally discovered by chemical means, prior to any of their biological activities having been identified. PP was discovered in a prominent chromatographic peak seen during the purification of chicken insulin (Kimmel et al. 1975) and, via a chemical assay which detects the presence of peptides containing the C-terminal alpha amide structure, PYY was detected in porcine intestinal extracts (Tatemoto 1982a) and NPY was detected in porcine brain extracts (Tatemoto 1982b) . Initial studies localized PP and PYY to endocrine-type cells in the endocrine pancreas (Schwartz 1983 ) and distal intestine (Lundberg et al. 1982a ) respectively; postprandial plasma elevations of PYY and PP levels occur (Schwartz 1983 , Taylor 1989 , consistent with these peptides having a humoural mechanism of action. In contrast, NPY was reported to be confined to neural structures in the peripheral, enteric and central nervous systems (Lundberg et al. 1982b , Furness et al. 1983 , consistent with NPY predominantly functioning as a neurotransmitter/neuromodulator. However, our recent demonstration that PYY (McDonald et al. 1993 , Wang et al. 1997 ) rather than NPY is the predominant neuropeptide in the canine enteric nervous system, is consistent with PYY having both neurotransmitter/neuromodulator and hormonal modes of action and with PYY having a greater spectrum of activities than was initially recognized.
We recently reported that the gastrin releasing peptide (GRP), a neuropeptide in adult mammals, and apparently novel GRP-like peptides are present in the circulations and products of conception of ovine (Fraser et al. 1992 , Xiao et al. 1996a ) and human pregnancy (Xiao et al. 1996b) . This surprising finding stimulated us to screen for further unexpected presences of regulatory peptides in tissues associated with human pregnancy. This study reports that, similar to GRP, PYY is also present in the products of human pregnancy. It also describes the anatomical locations and molecular forms of PYY which occur in such tissues.
Materials and Methods

Tissue collection
Within five minutes of normal term parturition, five human placentae were immediately separated into amnion, chorion/decidua, and placental villi. The separated tissues were frozen immediately in liquid nitrogen and stored at 70 C until the time of extraction. Similarly, portions of human placentae obtained at various gestational ages were immediately fixed in 100 ml phosphate buffered saline (PBS) containing 4% paraformaldehyde-0·2% glutaraldehyde for immunohistochemistry (IHC). These tissues were obtained as waste products of pathological specimens according to the procedures outlined by the Human Ethics Committee at the University of Western Ontario. For IHC, pathology archival tissue from first trimester abortion was obtained from Dr C Goodyer (Montreal Childrens' Hospital, Montreal, Canada). Second trimester human fetal tissue was obtained following therapeutic abortion, by Dr D Hill at the Northern General Hospital, Sheffield, UK, with local ethical approval.
Tissue extraction
Thawed tissues were boiled immediately (95 C, 10 min) in 10 volumes water per unit of tissue wet weight, to inactivate proteolytic enzymes and denature structural proteins. The extraction solutions were cooled, and trifluoroacetic acid (TFA) and acetonitrile were added to make the solutions 2% and 10% (v/v) respectively. The tissues in the extraction solutions were homogenized using a hand-held (OMNI 1000) homogenizer (OMNI International, Waterbury, CT, USA) and the extraction mixture stirred for 1 h at 4 C. The extracted tissues were removed from the supernatant by centrifugation and the pellets re-extracted with 1 M acetic acid at 4 C for 1 h. The supernatants from the two extraction procedures were lyophilized. The efficiency of the extraction process for PYY was estimated as 65·9 3·9% (mean ...; n=6) by the addition of radiolabelled PYY 1-36 to heatinactivated tissues. The tissue quantities of PYY-like immunoreactivity reported here have not been corrected.
Radioimmunoassay procedures
Radioimmunoassay (RIA) for PYY was performed using the antiserum designated LR-57. The characteristics of this antiserum, the preparation of radiolabelled PYY and the details of RIA performance have been described (McDonald et al. 1993) . Briefly, this antiserum was raised in rabbits against porcine PYY 1-36 (Penninsula, Belmont, CA, USA) and has no cross-reaction with PP or any structurally unrelated regulatory peptide tested, less than 0·03% cross-reaction with porcine NPY and recognizes PYY 3-36 and PYY 1-36 with equal potency. The final dilution of the antiserum used in the RIA was 1:400 000. The amount of synthetic porcine PYY added to the reaction mixture which decreased the initial binding of radiolabelled PYY (no unlabelled PYY added) by 10% was 2·5 fmol per assay tube, and that causing a 50% decrease in binding was 30 fmol per tube.
RIA for human PP was performed using an antiserum against PP designated 615-1054B-24A-19 (a generous gift of Dr R E Chance, Eli Lilly Laboratories, Indianapolis, IN, USA), the characteristics of which have been described in detail (Taylor et al. 1978) . Briefly, human PP (Bachem, Torrance, CA, USA) was radiolabelled with carrier-free I 125 (Amersham, Toronto, ONT, Canada) using the Chloramine-T method as described by McDonald et al. (1993) . After a preliminary purification of the iodination reaction mixture on a pre-washed Sep Pak C-18 cartridge (Waters Associates, Mississauga, ONT, Canada), the reaction mixture was further purified by reverse-phase HPLC using a Waters Associates apparatus and a µBondaPak C-18 column (Waters Associates). The solvent systems used were: (A) 0·12% (v/v) TFA (Sequenal grade, Pierce Chemical Company, Rockford, IL, USA) in water and (B) 0·1% (v/v) TFA in acetonitrile (Fisher Scientific, Toronto, ONT, Canada). The HPLC purification procedure employed a 35% B isocratic elution, and the radiolabelled ligand eluting at 18 min was used for RIA. Human PP was used as standard in the RIA. The antiserum was used in a final dilution of 1:2 000 000 in a total assay volume of 1 ml per tube. The buffer system employed was a 0·04 M phosphate buffer, pH 7·4, containing 0·05% sodium azide (w/v), 0·1 M sodium chloride, and 0·1% BSA (w/v). Bound and free radiolabelled ligand were separated using a charcoal-dextran technique (McDonald et al. 1993) . The amount of synthetic human PP added to the reaction mixture which decreased the initial binding of radiolabelled PP (no unlabelled PP added) by 10% was 0·3 fmol PP per assay tube, and that causing a 50% decrease in binding was 2·5 fmol per assay tube.
Chromatographic procedures
Gel filtration chromatography was performed using 1 120 mm Sephadex G-50 (sf ) columns (Pharmacia, Montréal, PQ, Canada), equilibrated and eluted with a 1 M acetic acid solution containing 0·15 M sodium chloride. The void volume (V o ) and total volume (V t ) of the columns were defined by the elution positions of Dextran Blue (Pharmacia) and carrier-free sodium I 125 (Amersham) respectively. Tissue extract samples or synthetic human PYY 1-36 , both dissolved in the acetic acid/NaCl solution, were added in 1 ml volumes to the columns. One millilitre fractions were collected and lyophilized prior to RIA.
Reverse-phase HPLC was performed using a Beckman System Gold HPLC with Phenomenex (Phenomenex, Torrance, CA, USA) reverse-phase C-18 columns (3·9 300 mm). The solvent systems used were: (A) 0·12% (v/v) TFA in water and (B) 0·1% (v/v) TFA in acetonitrile. The solvent flow rate was 1 ml/min and elution was performed using either of two gradient elution conditions. Elution conditions I consisted of sequential linear gradient elutions of: (1) 30-44% B over 60 min, (2) 44-65% B over 30 min, (3) 65-100% B over 10 min and (4) 100% B for 10 min. Elution conditions II consisted of sequential linear gradient elutions of: (1) 29-31% B over 60 min, (2) 31-65% B over 30 min, (3) 65-100% B over 10 min and (4) 100% B for 10 min. The reverse-phase C-18 columns were calibrated with synthetic human PYY 1-36 , human NPY and human PP using gradient I elution conditions, and with human PYY 1-36 and PYY 3-36 (Bachem) using gradient II elution conditions. The elution positions of these peptides were established by monitoring UV absorption at 215 nm. Following calibration of the columns with standard peptides, the column and apparatus were thoroughly washed and blank chromatography runs were performed to ensure no carry-over of injected peptides.
Lyophilized tissue extracts with sufficient quantities of PYY-like immunoreactivity (PYY-LI) were partially purified by adsorption onto pre-washed C-18 Sep-Pak cartridges. The peptides adsorbed onto the cartridges were washed with 0·1% (v/v) TFA in water, eluted with an acetonitrile:water:TFA mixture (80%:19·9%:0·1%) and the peptides recovered from the eluates by partial evaporation of the acetonitrile and TFA under reduced pressure followed by lyophilization. Sufficient quantities of either partially purified tissue samples or standard synthetic peptides for calibration were dissolved in 1 ml solvent A and injected onto the C-18 HPLC columns. One millilitre eluate fractions were collected using gradient I elution conditions and 0·5 ml fractions were collected using gradient II elution conditions. Each collection tube contained 0·1 mg BSA (Sigma, St Louis, MO, USA) and all eluate fractions were lyophilized prior to RIA.
Three separate samples each of human amnion and placental extracts and two samples of fetal intestinal extracts were subjected to gel filtration and reverse-phase HPLC under both gradient elution conditions. The lyophilized eluate fractions obtained from the gel filtration or reverse-phase HPLC columns were reconstituted in appropriate volumes of RIA buffer prior to assay for PYY-LI.
Immunohistochemistry
Samples of chorion/decidua, amnion and placenta, fixed in a 4% paraformaldehyde-0·2% glutaraldehyde solution, were embedded in paraffin and sectioned at a thickness of 5 µm (Sangha et al. 1994) . Samples processed and examined for PYY-LI included tissues from first trimester (n=4), second trimester (n=11), third trimester (n=10) and from term cases (n=17). Immunohistochemistry, using the antiserum LR-57 (see RIA procedures for antiserum characteristics) at dilutions between 1:500 and 1:1000, was performed by the avidin-biotin peroxidase method as previously described (Sangha et al. 1994) . The specificity of the immunohistochemical staining was tested by preabsorption of the antiserum with synthetic human PYY and NPY (incubation of the antiserum with solutions of 100 µg per ml peptide overnight at 4 C). A further control included the primary antibody being replaced with non-immune rabbit serum.
Results
Amounts and chromatographic forms of PYY-LI
All tissue extract samples were assayed at multiple dilutions and the dose-inhibition curves produced by all samples parallelled those produced by synthetic human PYY. The amounts of PYY-LI were found to be highest in the term human amnion extracts at 4·36 2·79 pmoles/g tissue wet weight (mean ...; n=5). The term placental extracts contained 2·78 0·50 (n=5) and the term decidua/ chorion extracts 0·68 0·68 (n=5) pmoles PYY-LI/g wet weight. Similar to previous findings for GRP (Fraser et al. 1992 , Xiao et al. 1996b , there was variability in the amounts of measured PYY-LI between samples, especially in the decidua/chorion extracts. For comparison, the PYY-LI content in second trimester human fetal intestinal extracts was higher at 14·35 3·45 pmoles/g wet weight (mean ...; n=3). There was no detectable PP-like immunoreactivity seen in any sample of the chorion/ decidua, placental villi or amniotic tissue extracts (n=5 for each tissue).
Portrayed in Fig. 1 are the reverse-phase HPLC gradient I elution PYY-LI profiles (panels A, B, C) produced by human amnion, placental, and second trimester fetal intestinal tissue extracts. Panel D in Fig. 1 shows the PYY-LI profile produced by human amniotic tissue extracts on gel filtration chromatography. On reverse-phase HPLC using gradient I elution conditions, a dominant peak of PYY-LI was seen in all of the tissue extracts which occurred precisely at the retention time of human PYY (Fig. 1A,B,C) . Minor amounts of PYY-LI eluting at an earlier retention time were seen in the fetal intestinal tissue extracts (Fig. 1C) . No PYY-LI was seen at the elution times of NPY or PP, nor at any later elution time in any of the sample chromatograms (Fig. 1) . A single peak of PYY-LI appeared at the elution volume of synthetic human PYY 1-36 on gel filtration chromatography of human amnion (Fig. 1D ), placental and second trimester fetal intestinal tissue extracts (data not shown).
Reverse-phase HPLC extracts of amnion, placental and fetal intestinal tissue under higher HPLC resolution conditions (gradient II), resolved the major PYY-LI entity into two distinct immunoreactive peaks, eluting precisely at the retention times of human PYY 1-36 and PYY (Fig. 2) . Approximately equal amounts of the two molecular forms were seen in all chromatographs performed. In both gradient I and II elution conditions, the fetal intestinal extracts ( Figs 1C and 2C ) produced slightly heterogenous profiles as minor amounts of earlier eluting peaks of unknown identity were present. Figure 3 portrays the immunohistochemical distribution of PYY-LI in the human intrauterine tissues of pregnancy. At the earliest gestation time studied (9·5 weeks), intense cytoplasmic staining for PYY-LI was present in the syncytiotrophoblast and cytotrophoblasts of the chorionic villi (Fig. 3A) . There was also intense positive cytoplasmic staining for PYY-LI in the invasive (intermediate) trophoblasts of the decidual septa at 9·5 weeks. At term (39 weeks), positive staining for PYY-LI of the syncytiotrophoblast and invasive intermediate trophoblasts of the decidual septa remained present (Fig. 3B) . Term fetal membranes contained positive staining for PYY-LI in amniotic epithelial cells and in chorionic trophoblasts (Fig.  3C) . Positive staining was also seen in maternal decidual cells but the precise identity of these positively stained cells has not yet been established (Fig. 3C) . PYY-LI staining patterns in second and third trimester tissues were identical to those seen at 9·5 weeks and at term. Preabsorption of the PYY antiserum with PYY either abolished or greatly diminished the positive staining for PYY (Fig. 3D,E,F) .
Anatomical locations
Pre-incubation of the antiserum with NPY did not affect staining for PYY and non-immune rabbit serum did not produce positive staining (data not shown).
Discussion
This is the first study to demonstrate the presence of PYY 1-36 and PYY 3-36 in human placenta and fetal membranes; PYY-LI was found to be present in these intrauterine tissues as early as 9·5 weeks of gestation and remained present throughout pregnancy to term. Previous studies had reported the presence of NPY in human placenta (Petraglia et al. 1989 (Petraglia et al. , 1993 but did not report investigations into the presence of other PP family members.
Gel filtration chromatography and low resolution reverse-phase HPLC produced concordant results demonstrating a single peak of PYY-LI occurring at the elution position of PYY 1-36 in term products of human conception and human second trimester fetal intestinal tissue extracts. Using higher resolution reverse-phase HPLC conditions, this PYY-LI peak resolved into two distinct peaks coeluting with PYY 1-36 and PYY . Similar to previous findings in human blood (Grandt et al. 1994 ) and canine adult intestine (Grandt et al. 1992) , term products of human conception and the human fetal intestinal extracts contain approximately equal amounts of these molecular forms.
The PYY 3-36 molecular form probably arises from post-translation processing of PYY 1-36 by the high specific activity enzyme, human dipeptidyl peptidase IV (Mentlein et al. 1993) . Similarly, endogenous NPY 3-36 has been isolated recently from porcine brain tissue extracts (Grandt et al. 1996) . Of note, human neonates and infants have elevated cord and peripheral blood levels of PYY-LI and, on gel permeation chromatography, the majority of this plasma PYY-LI appears to be of a similar size as PYY 1-36 (Adrian et al. 1986) . Although the physiological significance of the presence of either PYY 1-36 or PYY 3-36 in human products of conception is unknown, these results suggest that, as is the case with the enteric nervous system, PYY has been an under-investigated peptide relative to its better known family member, NPY. PYY-LI is expressed early in pregnancy and remains present to term in the cytotrophoblasts, syncytiotrophoblast, invasive intermediate trophoblasts and in amniotic epithelial cells. These cell types produce a number of biologically active agents and conceivably either or both PYY 1-36 and PYY 3-36 may function in a paracrine or endocrine fashion to regulate the release of such agents.
At least five receptor subtypes interacting with PP peptide family members have been either cloned or identified by pharmacological studies, the Y1 and Y2 subtypes possibly being of most relevance to this study. The Y1 receptor (Herzog et al. 1992 , Krause et al. 1992 , Larhammar et al. 1992 requires an intact N-terminal region of NPY or PYY for high affinity binding. It binds NPY, PYY and (Leu 31 , Pro 34 )-NPY with equal potency but has much lower affinity for PP and C-terminal fragments of ). The Y2 receptor subtype (Gerald et al. 1995 , Rose et al. 1995 , Gehlert et al. 1996 binds NPY, PYY and C-terminal fragments of both molecules with equal potency; much lower affinity binding is seen using either PP or (Leu 31 , Pro 34 )-NPY as ligands. The Y1 receptor subtype is expressed in human placenta (Wharton et al. 1993) , selectively localized to the syncytiotrophoblast, with other regions containing considerably lower levels of the message coding for this receptor subtype. As NPY has been demonstrated to result in the release of corticotrophin releasing factor from cultured human placenta cells (Petraglia et al. 1989 (Petraglia et al. , 1993 , it will be of interest to determine if PYY 1-36 also has this action and if the action is mediated by the Y1 receptor subtype. The function of the PYY 3-36 molecular form is at present also unknown. PYY 3-36 would not be expected to interact with the Y1 receptor with high affinity and the presence of the Y2 receptor subtype in pregnancyassociated tissues has not been reported, as yet. Conceivably, the production of PYY 3-36 from PYY 1-36 may act as a regulatory mechanism to control the amount of available PYY 1-36 interacting with the Y1 receptor. Alternatively, PYY 3-36 could exert a unique activity via interaction with the Y2 receptor subtype, if such is shown to be present in these tissues by future studies.
Although the trophic effects of PYY or NPY have not been extensively investigated, there are reports suggesting that these peptides do have effects on growth. PYY administration is reported to be trophic to the duodenum of the nursing but not the adult rat, and to increase significantly the weight and DNA content of the duodenum, ileum and colon of adult mice (Guan et al. 1993 , Gomez et al. 1995 . Interestingly, PYY inhibits cholecystokinin-stimulated pancreatic growth in adult rat and inhibits the growth of human pancreatic cancer cell lines via interaction with the Y2 receptor subtype (Liu et al. 1995a,b) . NPY produces mitogenic effects on human and rat vascular smooth muscle cells (Zukowska-Grojec et al. , Erlinge et al. 1994 ) and on adult rat ventricular myocytes (Millar et al. 1994) ; the mitogenic effects in these reports were mediated by the Y1 receptor subtype. The presence of PYY 1-36 and the Y1 receptor subtype in human products of conception is consistent with a potential trophic role for PYY 1-36 in placental and possibly fetal development. Potential roles for PYY in trophism would require the presence of a receptor sub-type capable of recognizing PYY 3-36 with high affinity.
In summary, we have demonstrated the presence of PYY 1-36 and PYY 3-36 in human maternal and fetal placental membranes. PYY-LI appears early in pregnancy and remains present to term. Functional studies on PYY and its interactions with specific receptor subtypes during pregnancy are required.
